Murianni Veronica, Cerbone Luigi, Rescigno Pasquale, Catalano Fabio, Damassi Alessandra, Cremante Malvina, Gandini Annalice, Puglisi Silvia, Pesola Guido, Banna Giuseppe Luigi, Buti Sebastiano, Signori Alessio, Fornarini Giuseppe, Rebuzzi Sara Elena
Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132, Genova, Italy.
Mesothelioma & Rare Cancer Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121, Alessandria, Italy.
Immunotherapy. 2022 Dec;14(18):1419-1427. doi: 10.2217/imt-2022-0150. Epub 2023 Jan 4.
Immune checkpoint inhibitors have significantly improved the therapeutic scenario of many different advanced malignancies and could be an effective treatment strategy in synchronous or metachronous tumors. The authors describe the clinical case of a patient who experienced a long-lasting response of his metastatic renal cell carcinoma and an optimal response of his locally advanced cutaneous squamous cell carcinoma to immunotherapy. The systemic treatment was chosen based on a literature review of several clinical reports, since there was no prospective study on anti-PD-1 blockade activity in cutaneous squamous cell carcinoma when the patient started the treatment. This clinical case supports the growing evidence for immunotherapy as a valid treatment option across different types of advanced tumors.
免疫检查点抑制剂显著改善了许多不同晚期恶性肿瘤的治疗情况,并且可能是同步或异时性肿瘤的一种有效治疗策略。作者描述了一名患者的临床病例,该患者的转移性肾细胞癌对免疫疗法产生了持久反应,局部晚期皮肤鳞状细胞癌也有最佳反应。由于在患者开始治疗时,尚无关于抗PD-1阻断在皮肤鳞状细胞癌中活性的前瞻性研究,因此基于对多篇临床报告的文献综述选择了全身治疗。该临床病例支持了越来越多的证据,表明免疫疗法是跨不同类型晚期肿瘤的有效治疗选择。